Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a single rituximab infusion tame Immunotherapy's harsh side effects?

NCT ID NCT07694414

Not yet recruiting Disease control Sponsor: Inge Marie Svane Source: ClinicalTrials.gov ↗

First seen Jul 10, 2026 · Last updated Jul 23, 2026 · Updated 2 times

Summary

This trial investigates whether a single ultra-low dose of rituximab can safely manage immune-related side effects caused by checkpoint inhibitor therapy in people with malignant melanoma. Participants receive one 100 mg infusion of rituximab along with a steroid tapering plan and are followed for six months. The study focuses on safety and whether rituximab helps control symptoms better than steroids alone.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
rituximab
What this could lead to
If successful, this could offer a safer, faster way to control severe immune side effects from cancer immunotherapy, reducing reliance on steroids.
What could go wrong
This is a small early-phase trial, so results may not apply broadly. Rituximab carries risks like infusion reactions and increased infection risk.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IMMUNE-RELATED ADVERSE EVENTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IMMUNE-RELATED ADVERSE EVENTS

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • National Center for Cancer Immune Therapy, Department of Oncology, Herlev Hospital

    Herlev, Herlev, 2730, Denmark

    Contact Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.